Disorders of the Nervous System

The Proline/Arginine Dipeptide from Hexanucleotide Repeat Expanded *C9ORF72* Inhibits the Proteasome

Rahul Gupta,^{1,2,*} **Matthews Lan**,^{3,*} **Jelena Mojsilovic-Petrovic**,⁴ **Won Hoon Choi**,⁵ **Nathaniel Safren**,⁶ **Sami Barmada**,⁶ **Min Jae Lee**,⁵ and **Robert Kalb**^{4,7}

DOI:<http://dx.doi.org/10.1523/ENEURO.0249-16.2017>

¹Department of Chemical and Biomolecular Engineering, School of Engineering and Applied Sciences, University of Pennsylvania, Philadelphia, PA, 19104, ²Department of Biology, College of Arts and Sciences, University of Pennsylvania, Philadelphia, PA, 19104, ³Department of Biochemistry, College of Arts and Sciences, University of Pennsylvania, Philadelphia, PA, 19104, ⁴Division of Neurology, Department of Pediatrics, Research Institute, Children's Hospital of Philadelphia, Philadelphia, PA, 19104, ⁵Department of Biochemistry and Molecular Biology, Seoul National University College of Medicine, Seoul 03080, Republic of Korea, ⁶Department of Neurology, University of Michigan, Ann Arbor, MI, 48109, and ⁷Department of Neurology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, 19104

Abstract

An intronic hexanucleotide repeat expansion (HRE) mutation in the *C9ORF72* gene is the most common cause of familial ALS and frontotemporal dementia (FTD) and is found in ~7% of individuals with apparently sporadic disease. Several different diamino acid peptides can be generated from the HRE by noncanonical translation (repeat-associated non-ATG translation, or RAN translation), and some of these peptides can be toxic. Here, we studied the effects of two arginine containing RAN translation products [proline/arginine repeated 20 times (PR₂₀) and glycine/arginine repeated 20 times (GR₂₀)] in primary rat spinal cord neuron cultures grown on an astrocyte feeder layer. We find that PR₂₀ kills motor neurons with an LD₅₀ of 2 μ M, but in contrast to the effects of other ALS-causing mutant proteins (i.e., SOD or TDP43), PR₂₀ does not evoke the biochemical signature of mitochondrial dysfunction, ER stress, or mTORC down-regulation. PR₂₀ does result in a time-dependent build-up of ubiquitylated substrates, and this is associated with a reduction of flux through both autophagic and proteasomal degradation pathways. GR₂₀, however, does not have these effects. The effects of PR₂₀ on the proteasome are likely to be direct because (1) PR₂₀ physically associates with proteasomes in biochemical assays, and (2) PR₂₀ inhibits the degradation of a ubiquitylated test substrate when presented to purified proteasomes. Application of a proteasomal activator (IU1) blocks the toxic effects of PR₂₀ on motor neuron survival. This work suggests that proteasomal activators have therapeutic potential in individuals with *C9ORF72* HRE.

Key words: ALS; frontotemporal dementia; lysosome-autophagy; motor neuron; proteasome

Significance Statement

Peptides made up of two alternating amino acids, proline/arginine (PR) or glycine/arginine (GR), are thought to contribute to the pathophysiology of familial ALS and frontotemporal dementia (FTD) caused by expansion of the intronic microsatellite repeat sequence GGGGCC in the *C9ORF72* gene. Here, we show that proline/arginine repeated 20 times (PR₂₀) is toxic to motor neurons and inhibits substrate flux through the proteasome and the lysosomal-autophagy pathway. Stimulation of the proteasome alleviates this toxicity, suggesting that targeting the PR₂₀-proteasome interaction may have therapeutic potential.

Introduction

ALS is an adult-onset, fatal neurodegenerative disease that manifests with progressive weakness, muscle wasting, spasticity, and respiratory failure (Wijesekera and Leigh, 2009), signs and symptoms that result from the death of upper and lower motor neurons (Rowland and Shneider, 2001). Approximately 10% of ALS cases are caused by single gene mutations; the remaining ~90% of cases are sporadic (Kiernan et al., 2011).

To date, the most common genetic abnormality underlying familial ALS is an expansion of the hexanucleotide sequence GGGGCC in the intron located between exons 1a and 1b of the *C9ORF72* gene (Renton et al., 2011; DeJesus-Hernandez et al., 2011). The majority of normal individuals have fewer than 8 GGGGCC repeats, whereas patients can have hexanucleotide repeat expansions (HREs) consisting of several hundreds or even thousands of repeats (Rutherford et al., 2012). Pre-mRNA transcripts containing the HRE adopt a G-quadruplex structure that can lead to sequestration of RNA-binding proteins and reduced abundance of the mature *C9ORF72* mRNA (Conlon et al., 2016; Lee et al., 2016; Lin et al., 2016). In some experimental platforms, the pathophysiology of *C9ORF72* HRE can at least partially be linked to these mRNA structures (Haeusler et al., 2014).

Additionally, the pre-mRNA produced from the HRE undergoes translation despite the lack of the ATG start codon. This repeat-associated non-ATG (RAN) translation results in the production of 5 different dipeptide repeat (DPR) proteins, depending on the reading frame and on the translation of the sense or antisense strand. The arginine-rich RAN translation products PR_n and GR_n as well as GA_n (where the *n* represents the number of dipeptide repeats) have been shown to result in neurodegeneration (Mizielinska et al., 2014; Zhang et al., 2014). Recent work establishes that DPRs can undergo cell-to-cell transfer (Westergaard et al., 2016).

The mechanism by which *C9ORF72*-associated RNA or DPR proteins impart toxicity onto cells is under active investigation. Although recent work points to defects in nucleocytoplasmic shuttling in *C9ORF72* HRE pathophysiology (Freibaum et al., 2015; Joviči et al., 2015; Zhang et al., 2015; Boeynaems et al., 2016), many questions remain. First, is HRE-mediated toxicity due to the HRE mRNA, DPR proteins, or both? Although several groups that have found defects in nucleocytoplasmic transport in the setting of *C9ORF72* HRE, they come to opposite conclusions regarding the toxic agent (Joviči et al., 2015; Freibaum et al., 2015; Zhang et al., 2015). Considering the differences in molecular structure between the HRE mRNA/DNA and DPR proteins, *a priori*, it seems unlikely that both would affect similar structures in the nuclear pore complex. Second, by what mechanism are impairments in nucleocytoplasmic shuttling injurious to cells and why are select neuronal populations affected? Essentially no information is extant on these issues. A system that unambiguously dissociates RNA from DPR protein toxicity could begin to provide insight into these pressing questions.

Here, we explore DPR protein toxicity by interrogating primary spinal cord neuronal cultures grown on an astrocyte feeder layer treated with synthetically produced proline/arginine repeated 20 times (PR₂₀) or glycine/arginine repeated 20 times (GR₂₀), obviating the distinction between DPR protein and mRNA-mediated toxicity. Unexpectedly, perturbed cellular processes previously implicated in genetic models of ALS (Kong and Xu, 1998; Betz and Hall, 2013; Saxena et al., 2013; Perera et al., 2014), such as mitochondrial dysfunction, ER stress, and mTOR down-regulation, were unaffected by PR₂₀ in this model. Instead, we find that PR₂₀ (but not GR₂₀) disrupts the activity of the ubiquitin-proteasome system (UPS) and the autophagy pathway. In addition, PR₂₀ (but not GR₂₀) associates with and directly inhibits proteasomes *in vitro*. We show that stimulating UPS activity protects against PR₂₀-mediated motor neuron death. The implication of the cellular protein degradation pathway in PR₂₀ toxicity suggests that the build-up of cellular proteins that are marked for degradation through ubiquitylation may result in RAN peptide-mediated *C9ORF72* HRE toxicity.

Materials and Methods

Antibodies

The following antibodies were used in this study: ubiquitin (Dako Z0458), phospho-P70 S6K (Cell Signaling, T389), P70 S6K (Cell Signaling, 9202S), phospho-4EBP1 (Cell Signaling, 2855S), 4EBP1 (Cell Signaling, 9452), phospho-AMPK (Cell Signaling, 2535S), AMPK (Cell Signaling, 2532S), HA (Roche, 3F10), α 3 (Enzo Life Sciences, MCP257), T7 (EMD Millipore, 69522) β -actin (Sigma A2066), anti-mouse and anti-rabbit Alexa Fluor 488 and 594 antibodies (Invitrogen), and anti-mouse and anti-rabbit IRDye antibodies (Li-Cor).

Culture generation

Mixed spinal cord neuron cultures were prepared as described previously (Mojsilovic-Petrovic et al., 2006).

Received August 19, 2016; accepted January 12, 2017; First published January 24, 2017.

The authors declare no competing financial interests.

Author contributions: R.G., R.K., and M.L. designed research; R.K., W.H.C., N.S., S.B., and M.J.L., performed research; R.G., M.L., J. M.-P., and N.S., contributed unpublished reagents/analytic tools; R.K. analyzed data; R.G., M.L., W.H.C., N.S., S.B., M.J.L., and R.K. wrote the paper.

This work is supported by National Institutes of Health Grants NS087077 and NS052325 (to R.G.K.) and NS072233 and R01-NS097542 (to S.B.), the National Research Foundation of Korea Grant 2016R1A2B2006507 and the Brain Research Program Grant 2016M3C7A1913895 (to M.J.L.), and the Roy & Diana Vagelos Scholars Program in the Molecular Life Sciences (M.L.).

*R.G. and M.L. are co-first authors.

Acknowledgements: We thank the generosity of Steve McKnight (University of Texas, Southwestern) for sharing synthetic peptides for initial studies and Daniel Finley (Harvard Medical School) for thoughtful discussions.

Correspondence should be addressed to either of the following: Robert Kalb at the above address, E-mail: kalb@email.chop.edu; or Min Jae Lee at the above address, E-mail: minjee@snu.ac.kr.

DOI: <http://dx.doi.org/10.1523/ENEURO.0249-16.2017>

Copyright © 2017 Gupta et al.

This is an open-access article distributed under the terms of the Creative Commons Attribution 4.0 International, which permits unrestricted use, distribution and reproduction in any medium provided that the original work is properly attributed.

Briefly, an astrocyte feeder layer was prepared from the cortex of newborn Sprague Dawley rat pups [postnatal day 2 (P2)] and grown to ~80% confluency. Subsequently, dissociated embryonic day 15 (E15) spinal cord neurons were added. One to two days later, AraC (5 mM) (catalog #C6645; Sigma) was added for 24 h to arrest astrocyte proliferation. Cultures were maintained in glia-conditioned medium supplemented with the following trophic factors (1.0 ng/ml each): human neurotrophin-3, human neurotrophin-4, human brain-derived neurotrophic factor, and rat ciliary neurotrophic factor (Alomone Labs). Half of the culture medium was replaced on a biweekly basis.

Toxicity assays and LD₅₀ determination of PR₂₀ or MG132

Days *in vitro* (DIV)14 mixed spinal cord cultures were exposed to PR₂₀ or GR₂₀ by addition of synthetic peptide to the media one time. Cultures were fixed 5 d later with freshly prepared 4% paraformaldehyde for 20 min, washed extensively with 0.1 M PBS, pH 7.4, and immunostained with SMI32 to identify motor neurons. Immunopositive cells >25 μ m in diameter are motor neurons based on their costaining for peripherin, ChAT, and islet 1/2 (Mojsilovic-Petrovic et al., 2006). Motor neurons were counted in three nonoverlapping, randomly selected fields on a coverslip using a 5[times objective, and the values from a single coverslip averaged. The results of 3-5 independently treated coverslips were the basis and means and variance used in statistical analysis. Each experiment was repeated with independently generated culture 4+ times (Mojsilovic-Petrovic et al., 2006).

To determine the LD₅₀ of DPR peptides, PR₂₀ or GR₂₀ was added once to the culture media of DIV14 cultures such that the final concentration varied from 2 nM to 35 μ M at approximately 10-fold increments. Motor neuron survival 5 d later was determined. Once the approximate LD₅₀ was determined, we repeated the analysis with more closely spaced concentrations for a more precise definition of the LD₅₀. Determination of the LD₅₀ of MG132 was accomplished in an identical manner.

For experiments involving IU1, DIV14 cultures were treated with PR₂₀ or its vehicle, and every other day, IU1 (or vehicle) was added to the culture media to achieve a final concentration of 5 μ M. At DIV19, cultures were fixed and motor neuron number determined as described above.

For experiments involving astrocytes only, freshly dissociated astrocytes were plated in 96-well dishes and maintained as above. Near confluent cultures were then exposed to various concentrations of PR₂₀ or GR₂₀ for 5 d and the XTT Cell Viability assay (Thermo Fisher Scientific, catalog #X6493) was performed per manufacturers guidelines. Absorbance at 450 nM was obtained using a BIO-TEK Synergy HT plate reader. This experiment was performed in triplicate.

PR₂₀ treatment for biochemical assays

Confluent dishes of astrocyte neuron cocultures at 37°C had volumes equalized to 2 ml of cell culture media each. Approximately 300 μ l of media from each dish was

removed and pooled with other dishes, PR₂₀ stock solution was added, and the mixture was then added back to the corresponding culture dish, so that each dish contained a final concentration of 2 μ M. All plates were incubated with PR₂₀ for 48 h.

Ubiquitylation assay

The ubiquitylation assay involved acute time point treatments with PR₂₀. 16 h prior to scheduled lysis, two dishes were treated to a final concentration of 2 μ M PR₂₀ using the methods described in the PR₂₀ treatment for biochemical assays subsection. This was repeated 8 h prior to lysis, 4 h prior to lysis, and 2 h prior to lysis. Samples were then lysed in RIPA buffer as described in Cell lysis for ubiquitin blots and processed for Western blot analysis.

MG-132 flux assay

MG-132 (Sigma) was used to inhibit proteasomal function. Cells were initially treated with PR₂₀ for a total of 48 h using the method outlined in PR₂₀ treatment for biochemical assays. Four hours prior to lysis, these cells were treated with MG-132 or vehicle. The MG-132 was kept in a stock solution in DMSO. This was added directly to culture to achieve a final concentration of 5 μ M. Cells were then lysed in RIPA buffer and immunoblotted for ubiquitin.

Cell lysis

Lysis buffer was prepared containing 1% (v/v) protease inhibitor cocktail, 1% (v/v) PMSF, and 1% (v/v) leucine in 1% RIPA buffer solution on ice. Culture dishes were washed once with ice-cold PBS to remove any remaining media. A total of 125 μ l (35-mm dish), 150 μ l (6-well plate), or 250 μ l (60-mm dish) of lysis buffer was added to each plate, and cells were scraped into a cold 1.5-ml tube. Samples were sonicated for 30 s at 20% intensity, placed on a rotator at 4°C for 20 min, and then centrifuged for 15 min at 13,200 rpm. Supernatant was then removed from each tube for further analysis.

Cell lysis for ubiquitin blots

Ubiquitin analysis requires the use of deubiquitinase (DUB) inhibitors. Lysis without these inhibitors runs the risk of degradation of the substrates to be targeted. As such, *N*-ethylmaleimide (Sigma), a potent DUB inhibitor, was used in the lysis buffer. The lysis buffer was prepared containing 1% (v/v) protease inhibitor cocktail, 1% (v/v) PMSF, 1% (v/v) leucine, and 50 μ M NEM in 1% RIPA buffer solution. The remainder of the lysis procedure follows Cell lysis.

Membrane stripping

Once scanning of the nitrocellulose membranes probed for 4EBP1/P-4EBP1 and S6K/P-S6K had been completed, Restore Western Blot Stripping Buffer (Thermo Fisher Scientific) was used to strip the blot of antibodies. The membranes were washed twice in PBS-T for 10 min each and then placed in the stripping buffer for 22 min. The membranes were then washed twice once again in PBS-T for 10 min. They were then placed in blocking

solution (5% w/v milk in PBS-T) for 45 min. This resulted in membranes with sample attached and no antibodies, ready to be probed for actin.

In vitro Ub-Sic1 degradation assays

Polyubiquitylated Sic1 proteins with PY degron motifs and T7 tag (Ub-Sic1) was prepared as previously described by Choi et al. (2016). Different concentrations of PR₂₀ peptides (0, 50, or 500 nM) and purified affinity-purified human proteasomes (5 nM) were preincubated 20 min in proteasome assay buffer [50 mM Tris-HCl (pH 7.5), 100 mM NaCl, 10% glycerol, 2 mM ATP, 10 mM MgCl₂, and 1 mM DTT] on ice, and 20 nM reconstituted Ub-Sic1 was subsequently added. Degradation of Ub-Sic1 and PR₂₀ peptides was monitored by immunoblotting using anti-T7 and anti-HA antibodies, respectively. Band intensities were quantified using ImageJ software (version 1.48k, NIH) from three independent immunoblotting assays ($n = 3$).

Direct interaction between PR₂₀ and human proteasomes

Whole-cell extracts from a stable HEK293T cell line harboring HTBH-tagged $\beta 4$ subunits were prepared as in Han et al. (2014) and incubated with HA-tagged PR₂₀ or GR₂₀ peptides (2 μ M) 2 h at 4°C. The resulting proteasome-dipeptide complexes were pull-downed with streptavidin agarose beads (Millipore) for 3 h at 4°C. Unbound proteasomes in the supernatants were discarded, and the pellets were mixed with 2 $\times$ SDS sample buffer. Different amounts of samples were resolved by SDS-PAGE/immunoblotting against HA and a proteasome core particle $\alpha 3$ subunit.

Autophagic flux assay

Primary spinal neurons were dissected from E15 rat pups and cultured at a density of 2.5×10^5 cells/ml on a laminin/poly-lysine-coated 96-well plate in motor neuron media. Four days after plating, neurons were transfected with Lipofectamine 2000 (Invitrogen). DNA-Lipofectamine mixtures were incubated with neurons for 20 min followed by rinsing. Neurons were then placed in 100 μ L of conditioned media that was collected immediately prior to transfection and half fresh motor neuron media containing 4 μ M PR₂₀, resulting in a final concentration of 2 μ M PR₂₀.

Optical pulse labeling experiments were performed using an automated microscopy platform previously described by Arrasate et al. (2004) and Barmada et al. (2014). A Nikon Eclipse Ti inverted microscope equipped with a PerfectFocus system, 20 $\times$ objective lens and an Andor iXon3 897 EMCCD camera were used to acquire images. Samples were illuminated with a Sutter Instruments Lambda XL lamp. The microscope and related components were encased in custom-built plexiglass enclosure set to maintain the temperature at 37°C and CO₂ at 5%. Semrock GFP and TRITC filters were used for excitation and detection. A Semrock 405-nm long-pass filter was used for photoactivation. Image acquisition and stage movements were accomplished in an automated fashion using μ Manager and original code written in BeanShell. For all experiments, photoconversion occurred

24 h following transfection. GFP and TRITC images were acquired immediately following activation and subsequently every 2 h for 12 h. Images were acquired in a similar 12-h window starting 48 h after PR₂₀ treatment. Using in-house image analysis scripts, neuronal cell bodies were identified based on their fluorescent intensity and morphology, and a ROI was drawn around the perimeter of each cell at each time. Single-cell TRITC intensity values were recorded and used to fit a first order exponential decay curve for individual neurons and calculate a Dendra2-light chain 3 (LC3) half-life for each cell.

Statistical analysis

To determine whether IU1 treatment had an effect on cell survival, a one tailed, one sample Student's t test was used to test the hypothesis that IU1 would improve cell survival when used with PR₂₀.

To test for group differences in the flux assay, a permutation test was used. This is a nonparametric statistical test that was implemented in MATLAB. The goal of the test was to determine whether the +MG132/−MG132 ratio changed significantly in the presence of PR₂₀. The test first quantifies this by taking the average of each experimental group and then finding the difference of ratios. It then permutes two samples located in two groups randomly, and determines that difference between averages again. This is repeated 50,000 times, and a histogram is plotted. This histogram represents the distribution of random noise in the sample. Since a higher difference in the +MG132/−MG132 ratio is a more “significant” result, the percentage of the random noise produced from 50,000 permutations that is higher in magnitude than the true difference (calculated from unpermuted data) is the p value.

Permutations of a data point in a +MG132 into a group labeled −MG132 (or vice versa) were not allowed. This is because these permutations would produce an obviously significant result, as MG132 is a known proteasomal inhibitor that significantly increases ubiquitin levels in the cell. Thus, this group difference was not interesting to us.

To assess group differences in the autophagic flux assay, the two-sided Kolmogorov–Smirnov test was used. This nonparametric test determines the probability that two continuous, one-dimensional probability distributions are drawn from the same distribution or not.

Results

PR₂₀ added to media is taken up by neurons and results in death

The difficulty of distinguishing between toxic HRE mRNA and DPR proteins has impeded our understanding of the mechanism underlying C9ORF72 HRE pathophysiology. As reported in *Science* (Kwon et al., 2014), the McKnight lab devised a strategy to overcome this problem: they studied U2OS cells and human astrocytes directly exposed to synthetic DPR proteins. They found that HA-tagged DPR proteins are taken up by these cells and evoke a variety of biochemical changes. PR₂₀ and GR₂₀ were shown to be toxic in a concentration range of 10–30 μ M depending on the specific assay. We built upon this

Figure 1. PR₂₀, but not GR₂₀, is toxic to motor neurons: kinetics of cellular accumulation and disposal. Mixed spinal cord neuron cultures or pure astrocyte cultures were exposed to PR₂₀- or GR₂₀-containing media; survival assays and biochemical interrogations followed. **A**, The survival of motor neurons was determined 5 d after exposure to various concentrations of PR₂₀. The LD₅₀ of PR₂₀ is ~ 2 μM. **B**, The survival of astrocytes was determined using the colorimetric XTT assay 5 d after exposure to various concentrations of PR₂₀ or GR₂₀. No death was seen up to 10 μM DPR. **C**, The survival of motor neurons was determined 5 d after exposure to various concentrations of GR₂₀. No death was seen up to 35 μM GR₂₀. **D**, Immunoblotting for HA-tagged PR₂₀ at various time points after addition of 2 μM PR₂₀ to mixed spinal cord cultures. PR₂₀ is first detectable in cell lysates approximately 0.5 h after exposure and rises to a maximum at 1.0-2.0 h. The Western blot signal declines thereafter and is undetectable at the 48-h time point. **E**, In a 2-h pulse-chase paradigm after 2 μM PR₂₀ application, Western blot signal is detectable in the soluble and insoluble fractions at the 2-h time point, and the signal diminishes thereafter to a barely detectable level by the 6-h time point. **F**, In a 2-h pulse-chase paradigm after 10 μM GR₂₀ application, Western blot signal is detectable in the soluble fraction only at the 2-h time point, and the signal diminishes thereafter to a barely detectable level by the 4-h time point. **G**, Mixed spinal cord cultures were pulsed for 2 h with 2 μM PR₂₀ and the chase media contained MG132 (5 μM) or vehicle. Cell lysates were prepared at time intervals thereafter, and quantitative image analysis of the resultant Western blots showed that the decrement in PR₂₀ abundance was the same in the +MG132 condition in comparison with the -MG132 condition. **H**, Mixed spinal cord cultures were pulsed for 2 h with 2 μM PR₂₀, and the chase media contained bafilomycin A1 (Baf A1) (400 nM). Cell lysates were prepared at time intervals thereafter, and quantitative image analysis of the resultant Western blots showed that the decrement in PR₂₀ abundance was the same in the +Baf A1 condition in comparison with the -Baf A1 condition.

approach by applying synthetic, HA-tagged, PR₂₀ or GR₂₀ dipeptides to cultures of rat spinal cord neurons grown on an astrocyte feeder layer, referred to as mixed spinal cord cultures hereafter. We find that PR₂₀ is toxic to cells: 5 d after a single application of PR₂₀, we observe the death of motor neurons with a LD₅₀ of 2 μM (Fig. 1A). No significant motor neuron death was seen with 2 μM PR₂₀ at the 48-h time point. In pure astrocyte cultures, we found no cell death when PR₂₀ was applied up to 10 μM (Fig. 1B). In this assay, GR₂₀ was neither toxic to motor neurons

when administered up to 35 μM (Fig. 1C) nor astrocytes when administered up to 10 μM (Fig. 1B).

Kwon et al. (2014) show that 30 min after application to U2OS cells or human astrocytes, PR₂₀ accumulates in the nucleus, colocalizing with the nucleolar protein fibrillin. This demonstrates that cells can take up extracellular DPR proteins, which is consistent with the recent demonstration of cell-to-cell transfer of DPRs *in vitro* (Westergard et al., 2016). We investigated the fate of PR₂₀ in mixed spinal cord cultures through immunoblotting and

immunocytochemistry. After application of 2 μ M PR₂₀, the immunoblot signal is first detected after 30 min and is maximal at the 1- to 2-h time points (Fig. 1D). Despite the continual presence of PR₂₀ in the media, the immunoblot signal diminishes over time and is undetectable at the 48-h time point. To gain further insight into the kinetics of the observed decrease in PR₂₀ levels in cell lysates over time, we pulsed cells with 2 μ M PR₂₀ for 2 h, washed, replaced with fresh media (lacking PR₂₀), and made cell lysates at regular intervals thereafter. Upon probing for PR₂₀ in the soluble and insoluble fractions of cell lysates, we saw maximal immunoreactivity at the 2-h time point and a rapid decline in soluble and insoluble PR₂₀ over the subsequent 4 h (Fig. 1E). After a single 2-h application of 2 μ M GR₂₀, the peptide is weakly detectable by immunoblotting in mixed spinal cord lysates. To more easily follow GR₂₀ by immunoblotting, we applied 10 μ M GR₂₀ to cultures and performed the same kinetic analysis as described in Figure 1D. In this assay system, GR₂₀ is detectable in cell lysates as early as 15 min and maximally accumulates in cells over the first hour of exposure. GR₂₀ immunoblot signal falls off rapidly thereafter and is undetectable at the 24-h time point. In the pulse-chase assay, GR₂₀ is maximal at the 2-h time point (immediately after the removal of GR₂₀ containing media) and is rapidly cleared from the soluble fraction of cells over the next 2-4 h (Fig. 1F). GR₂₀ is not detectable in the insoluble fraction under these assay conditions. To determine whether the proteasome was involved in the decrease in PR₂₀ abundance, we compared the kinetics of the PR₂₀ signal when MG132 or vehicle was included in the chase media. The loss of PR₂₀ was indistinguishable under these two conditions (Fig. 1G). Parallel studies using bafilomycin A1 in the chase media indicated that the lysosomal-autophagy system was similarly uninvolved in the decrease abundance in PR₂₀ over time (Fig. 1H).

Immunocytochemical examination at the 2-h time point reveals nuclear PR₂₀ immunoreactivity in motor neurons [identified by colocalization with a validated motor neuron marker, SMI32 (Mojsilovic-Petrovic et al., 2006); Fig. 2A--C] and other cells including astrocytes (Fig. 2D--F). Irregularly-shaped punctate accumulations of PR₂₀ immunoreactivity are also visible; some appear to be intracellular and others extracellular (best seen in Figure 2B,E). Immunocytochemical examination of mixed spinal cord cultures exposed to 2 μ M GR₂₀ for 2 h reveals cytosolic GR₂₀ immunoreactivity in motor neurons and other cells (Fig. 2G--I), but not astrocytes (Fig. 2J--L).

We draw a number of conclusions from these experiments. First, PR₂₀ is toxic to motor neurons with an LD₅₀ of 2.0 μ M, a value that is 25% of the LD₅₀ of 8.4 μ M reported by Kwon et al. (2014) that kills human astrocytes. We do not see the astrocytic DPR toxicity which we attribute to procedural differences: (1) Kwon et al. used human astrocytes, whereas we used freshly prepared rat astrocytes; and (2) we applied DPRs once, whereas Kwon et al. did so repeatedly.

Second, when cells contain the maximal amount of PR₂₀ (approximately 2 h after treatment), we observe that it accumulates in the nuclei of neurons and astrocytes. As

such, PR₂₀ acting directly on neurons may be noxious and/or a sublethal insult to astrocytes might be contributing to motor neuron death. Although punctate accumulations of PR₂₀, as reported previously (Wen et al., 2014), are also visible, the extent to which nuclear or punctate PR₂₀ confers toxicity is not known.

Third, even at a ~20 times higher concentration, GR₂₀ is not toxic to motor neurons. When cells contain the maximal amount of GR₂₀ (approximately 2 h after treatment), we find that it selectively accumulates in the cytosol of neurons only. Possible explanations for the benignity of GR₂₀ in our system are that the nucleus is the site of DPR protein toxicity and/or that astrocytes contribute to motor neuron injury. The absence of GR₂₀ in either or both of these locales apparently renders motor neurons largely insensitive to GR₂₀.

Fourth, PR₂₀ accumulates to a higher degree and for a longer time than GR₂₀ in cells, although the half-life of these dipeptides is similar (on the orders of hours). Neither the ubiquitin-proteasome nor the lysosome-autophagy pathway is likely to be responsible for the time-dependent loss of PR₂₀. Owing to how we crafted the sensitivity of Western blotting for DPR proteins, we are probably underestimating the relative abundance of these proteins in our cell lysates. Thus, we suspect that DPR proteins are not completely eliminated from cells within 48 h. It is noteworthy that HA-tagged PR₂₀ and GR₂₀ have similar molecular weights (6.1 vs 5.3 kDa, respectively) and identical calculated isoelectric point (e.g., pI = 12.37). This suggests that the biological effects of small basic peptides are sequence dependent, implying that they interact with distinct intracellular molecules.

PR₂₀ does not significantly impact mTORC, ER stress, or mitochondrial dysfunction

Cell and animal models of ALS based on the expression of mutant proteins that cause familial ALS (e.g., mTDP43, mSOD1) have implicated reduced mTORC activity, mitochondrial dysfunction, and ER stress (Kong and Xu, 1998; Lim et al., 2012; Betz and Hall, 2013; Saxena et al., 2013; Perera et al., 2014) in the pathophysiology. To understand the mechanism underlying DPR protein toxicity, we asked whether PR₂₀ evoked similar biochemical changes in cells.

Upon treating cultures with 2 μ M PR₂₀ for 48 h, we used immunoblotting techniques to probe for these biochemical changes (Fig. 3A,B). We see no statistically significant differences in the activation level of the mTOR pathway (monitored by the abundance of phosphorylated S6K and 4EBP1), mitochondrial dysfunction (monitored by the abundance of phosphorylated AMPK), or ER stress (monitored by the abundance of KDEL-tagged chaperones BiP and PDI). Biochemical interrogations at earlier time points similarly show no effect of PR₂₀ on these pathways (data not shown). These observations suggest that in this experimental paradigm, PR₂₀ does not influence pathways previously implicated in mTDP43 and mSOD toxicity. One caveat here is that our culture system contains astrocytes, motor neurons, and other neurons and biochemical changes within a subpopulation of cells might be ob-

Figure 2. PR₂₀ and GR₂₀ accumulate in distinct subcellular locations and distinct cell populations. Mixed spinal cord cultures were exposed to 2 μ M PR₂₀ or GR₂₀ for 48 h, fixed, and processed for immunocytochemistry. **A**, Staining with SMI32 reveals large multipolar motor neurons. The inset shows a single 0.5- μ m slice from the confocal data at the level of the nucleus. **B**, The same field as in **A**, stained for HA-PR₂₀ reveals nuclear staining as well as scattered puncta. The inset shows a single 0.5- μ m slice at the same level as in **A**, suggesting nuclear PR₂₀ in the motor neuron. **C**, A merge image of **A** and **B** reveals nuclear PR₂₀ in multiple cells, including the labeled motor neuron. The inset shows the same single 0.5- μ m slice from **A** and **B** unambiguously demonstrating PR₂₀ immunoreactivity in motor neurons. Calibration bar = 35 μ m. **D**, Staining for GFAP reveals abundant astrocytes in these cultures. **E**, The same field as in **D**, stained for HA-PR₂₀ reveals nuclear staining as well as scattered puncta. **F**, A merge image of **D** and **E** reveals nuclear PR₂₀ in astrocytes. **G**, Mixed spinal cord cultures were exposed to 2 μ M GR₂₀ for 48 h, fixed, and processed for immunocytochemistry. Staining with SMI32 reveals large multipolar motor neurons. Inset shows a single 0.5- μ m slice from the confocal data at the level of the nucleus. **H**, The same field as in **G**, stained for HA-GR₂₀ reveals cytoplasmic staining. Inset shows a

continued

single 0.5- μ m slice at the same level as in **G**, suggesting cytoplasmic GR₂₀ in the motor neuron. **I**, A merge image of **G** and **H** reveals cytoplasmic GR₂₀ in multiple cells, including the labeled motor neurons. Inset shows the same single 0.5- μ m slice from the **G** and **H** unambiguously demonstrating GR₂₀ immunoreactivity in motor neurons. Calibration bar = 30 μ m. **J**, Staining for GFAP reveals abundant astrocytes in these cultures. **K**, The same field as in **J** stained for HA-GR₂₀ reveals cytoplasmic staining. **L**, A merge image of **J** and **K** reveals cytoplasmic GR₂₀ is not present in astrocytes.

scured when we generate cell lysates from this heterogeneous cell population. The cost of using maximally healthy astrocyte/neuronal cocultures that approximate the *in vivo* complexity of cell-cell interactions is the difficulty of studying the biochemistry of a distinct subtype of neuron.

PR₂₀ induces cytoplasmic degradation dysfunction through diminished proteasomal flux

A variety of disease-causing proteins can cause UPS inhibition (Bence et al., 2001). Thus, we asked whether PR₂₀ influences the ubiquitylation status of the proteome over time. Upon immunoblotting for total cellular ubiquitin at various time points after the application of PR₂₀ (vs vehicle) to cultures, we find that PR₂₀ treatment is asso-

ciated with a progressive increase in total ubiquitylated protein levels. This is statistically significant at the 2-, 8-, and 16-h time points (Fig. 4A). We considered the possibility that the smear of ubiquitin immunoreactivity might contain PR₂₀ immunoreactivity. When we performed immunoblots for HA in these samples, we saw all the PR₂₀ immunoreactivity ran at ~ 10 kDa, the molecular weight we see of pure peptide (Fig. 4A.). Thus, this assay provides no evidence that PR₂₀ is ubiquitylated.

The increase in the steady-state amount of ubiquitin over time could be attributed to an increase in the rate of ubiquitylation or a decrease in the rate of degradation of ubiquitylated substrates (Fig. 4B). This is analogous to the autophagy protein LC3-II whose increased abundance in

Figure 3. PR₂₀ neither influences the activation of TORC or AMPK nor ER stress. Mixed spinal cord cultures were exposed to PR₂₀ for 48 h and then processed for immunoblotting. **A**, Representative immunoblot images of biochemical markers of TORC activation (e.g., phospho-4EBP1 and phospho-S6K), AMPK activation, or activation of the ER stress response (KDEL) shows no difference between PR₂₀ versus vehicle-treated cells. **B**, Quantification of the bands with intensity values from samples were averaged and normalized to actin loading controls. Dark grey bars correspond to the presence of PR₂₀, and light grey bars correspond to levels without PR₂₀. Error bars represent SE.

Figure 4. Total ubiquitin levels rise over time in the presence of PR₂₀; PR₂₀, but not GR₂₀, inhibits substrate flux through the ubiquitin-proteasomal system. Mixed spinal cord cultures were exposed to PR₂₀ or GR₂₀ and subjected to biochemical interrogations. **A**, Duplicate or triplicate cell lysate samples probed for ubiquitin in the absence of PR₂₀ (-PR₂₀) or at 2, 4, 8, or 16 h after PR₂₀ application. A progressive build-up in total ubiquitin levels occurs over time. The panel below shows quantification of these data with total ubiquitin levels normalized to actin loading controls. Error bars represent SE. Blotting for HA-tagged PR₂₀ shows that DPR is present in the lysates but does not migrate as a high molecular weight species as would be expected if PR₂₀ was ubiquitylated. Equal amounts of total protein are present in each lane, as reported by the actin blot. **B**, Cartoon describing two different mechanisms for increased steady state ubiquitin levels: enhanced ubiquitylation versus decreased proteasomal degradation. **C**, Total ubiquitin levels from cells treated with PR₂₀ or vehicle for 48 h and then MG132 or vehicle for 4 h. The difference between the +/- MG132 lanes represents the flux of ubiquitylated substrates over 4 h. Representative ubiquitin blots demonstrate a smaller difference between the +/- MG132 lanes in PR₂₀-treated cultures versus vehicle-treated cultures. The permutation test was applied to determine whether statistically significant group differences exist, and the results are shown in the lower panel. There is a reduced flux of ubiquitylated substrates in the PR₂₀-treated cells versus vehicle-treated cells. Six independent biological replicates were tested for each condition. *, $p < 0.05$ by the permutation test. **D**, Representative ubiquitin blots demonstrate no difference between the +/- MG132 lanes in GR₂₀-treated cultures versus vehicle-treated cultures. The permutation test was applied to determine whether statistically significant group differences exist, and the results are shown in the lower panel. No group differences were found, and at least 10 independent biological replicates were tested for each condition. n.s., not significant.

cells under certain conditions can be attributed to an increase in the rate of production or a decrease in the rate of degradation (which reflects increased or decreased flux through the lysosomal-autophagy pathway, respectively). Although several approaches can be taken to resolve the mechanism, in the autophagy field, the turnover assay is most widely used: the difference in LC3-II levels between samples with or without an autophagy inhibitor (i.e., chloroquine or bafilomycin A1) is used to report flux (Mizushima et al., 2010; Klionsky et al., 2012). We have taken a similar approach here using MG-132, a potent proteasomal degradation inhibitor (Goldberg, 2012). The difference in the quantity of ubiquitylated proteins from cells treated with MG-132 for 4 h versus vehicle reflects the size of the ubiquitylated protein pool normally degraded by the UPS. The larger the difference, the more proteins are degraded. Thus, this is a measure of flux through the UPS.

Parallel sets of mixed cultures were treated with PR₂₀ or vehicle for 48 h, and subsequent experimental groups were treated with MG-132 or vehicle for 4 h. Upon lysis, whole-cell ubiquitin levels were determined through immunoblotting. The average of these was taken for the cases with and without PR₂₀. A two-tailed permutation test was performed with 50,000 iterations, and statistically significant ($p < 0.05$) group differences were found; proteasomal flux was reduced in the presence of PR₂₀ (Fig. 4C). In parallel, we examined the effect of GR₂₀ on total ubiquitin levels with or without MG-132. GR₂₀ neither influenced total ubiquitin levels nor proteasomal flux (Fig. 4D). Together with the finding of elevated total ubiquitylated protein levels in PR₂₀-treated (but not GR₂₀-treated) cultures over time, these observations suggest that PR₂₀ specifically acts as a proteasomal inhibitor.

We wondered how soon after application to cultures did PR₂₀ inhibit proteasomal flux. Specifically, at the time point when PR₂₀ appears maximally within cells (i.e., 2 h; see Figure 1D), was proteasomal flux impaired? We repeated the $\pm$ MG132 flux assay after 2 h of PR₂₀ exposure and found no statistically significance between the PR₂₀ versus vehicle-treated cells by permutation test ($n = 6$ per experimental group, 4 experimental groups, $p = 0.38$). This observation suggests that PR₂₀ accumulation in cells does not instantaneously lead to proteasomal inhibition. We suspect that the lag between PR₂₀ internalization and proteasomal inhibition is an “access” issue, and perhaps this is linked to ephemeral sequestration of DPR proteins in nonmembrane delimited compartments as recently demonstrated by the Taylor and McKnight labs (Lee et al., 2016; Lin et al., 2016). We did not look at time points later than 48 h, because we feared cell morbidity and mortality could have secondary effects on proteasomal function and thus lead to interpretative difficulties.

Since all of these biochemical experiments were performed on mixed spinal cord cultures, it is possible that the effects of PR₂₀ are more or less robust within a specific subpopulation of cells. Although the simplest conclusion is that all cells taking up PR₂₀ are manifesting the same biochemical phenotype, deployment of cell-

type-specific reporters of UPS flux could reveal differences otherwise obscured by our Western blots.

Autophagic flux is reduced in the presence of PR₂₀

We next asked whether PR₂₀ influences flux through the lysosomal-macroautophagy pathway (referred to as autophagy hereafter) as well. As mentioned above, one commonly used biochemical approach is to monitor changes in the amount of 1A1B-LC3, a microtubule-associated protein that acts as both an autophagy marker and substrate, in the presence or absence of an autophagy inhibitor (Mizushima et al., 2010; Klionsky et al., 2016). Unfortunately, this approach is not well suited to investigations using mixed cultures because of the difficulty of resolving the active, lipidated form of LC3, termed LC3-II, from the unmodified LC3-I using immunoblot techniques (Zhai et al., 2015). Moreover, traditional immunoblotting and immunocytochemical techniques can be insensitive and are often difficult to accurately quantify. To overcome these problems, we adopted an optical pulse labeling approach (Tsvetkov et al., 2013; Barmada et al., 2014) to monitor autophagic flux. In this technique, a Dendra2-LC3 fusion protein is introduced into cells. Upon exposure to 405-nm light, the excitation and emission spectra of Dendra2 are irreversibly red shifted. Because LC3 is an autophagy substrate, the rate of Dendra2-LC3 degradation (estimated by the time-dependent loss of red fluorescence) represents a measure of autophagic flux (Koga et al., 2011; Tsvetkov et al., 2013; Barmada et al., 2014; Loos et al., 2014). An example of this phenomenon is shown in Figure 5A.

Primary spinal neurons were transfected with a plasmid encoding Dendra2-LC3, and subject to optical pulse labeling using automated longitudinal fluorescence microscopy (Barmada et al., 2014). The half-life of Dendra2-LC3 was measured in thousands of primary spinal neurons on single-cell basis. Four experiment groups were investigated: (1) Dendra2-LC3 + vehicle; (2) Dendra2-LC3 + GR₂₀; (3) Dendra2-LC3 + PR₂₀; and (4) Dendra2-LC3 + MG132. We observed a wide distribution of neuronal Dendra2-LC3 half-lives in all groups (Fig. 5B), consistent with previous studies (Barmada et al., 2014). Treatment with 2 μ M PR₂₀ peptide led to a significant shift in the population distribution, with a reduction in the peak around $\sim$ 20 h and a longer tail of half-lives Dendra2-LC3 (Fig. 5B). Compared with the control, treatment with PR₂₀ extended the half-life of Dendra2-LC3 by $\sim$ 5.6 h ($p = 2 \times 10^{-16}$). Compared with the control, treatment with GR₂₀ to increase the half-life of Dendra2-LC3 by 1.5 h ($p = 0.0038$). Finally, compared with the control, MG132 led to a more marked rightward shift of the curve, and this treatment extended the half-life by 11.9 h ($p = 2.2 \times 10^{-16}$).

Next, we looked at the distribution of Dendra2 half-lives operating under the presumption that this soluble cytosolic protein is likely to be degraded by the UPS (Fig. 5C). Four experiment groups were investigated: (1) Dendra2 + vehicle, (2) Dendra2 + GR₂₀, (3) Dendra2 + PR₂₀, and (4) Dendra2 + MG132. Compared with the vehicle, MG132 treatment led to a marked rightward shift of the curve and

Figure 5. PR₂₀ inhibits flux through the lysosomal-autophagy system. **A**, Optical pulse labeling of spinal neurons using automated fluorescent microscopy. Following a pulse of 405-nm light, a portion of Dendra2-LC3 is photoconverted such that its peak emission is red-shifted to 573 nm. By measuring the decay in intensity using a TRITC filter, half-life can be determined in individual neurons. The half-life of Dendra2-LC3 is a measurement of autophagosome turnover, with an increased half-life indicating reduced turnover. **B**, Distribution of Dendra2-LC3 half-lives in cells treated with 2 μ M PR₂₀, GR₂₀, and 10 μ M MG132 compared with those treated with vehicle. * indicates $p < .05$ with the two-sided Kolmogorov-Smirnov (KS) test (GR₂₀ $p = 0.0038$, PR₂₀ $p = 2.2 \times 10^{-16}$, MG132 $p = 2.2 \times 10^{-16}$). **C**, MG132 significantly extends Dendra2 half-life while 2 μ M PR₂₀ and GR₂₀ do not (MG132 $p = 3.23 \times 10^{-5}$, two-sided KS test).

the difference between the Dendra2 half-life in MG132 versus vehicle-treated cells (32.3 vs 29.6 h) was statistically significant ($p = 3.23 \times 10^{-5}$). Dendra2 half-life in PR₂₀- or GR₂₀-treated cultures (30.5 and 31.0 h, respectively) did not differ in a statistically significant manner from vehicle-treated cells.

We draw a number of conclusions from these results. First, PR₂₀ (and to a far lesser extent GR₂₀) retards flux through the autophagy pathway. Second, to the degree that Dendra2 is degraded by the UPS, PR₂₀ and GR₂₀ had no statistically significant effect. Together, these observations suggest that PR₂₀ acts in a relatively selective manner to slow flux through the autophagy pathway. Third, inhibition of the proteasome impairs autophagic flux. This was an unexpected observation, since several

prior studies using cell lines have reported autophagy induction upon UPS inhibition (Ding et al., 2007; Lan et al., 2015; Bao et al., 2016). Our findings in neurons may indicate a cell-type-specific relationship between degradative pathways. Alternatively, a nonspecific toxicity to the autophagy pathway may occur when cell function is impaired by UPS blockage. Future work will be required to understand this effect of MG132 on autophagy in neurons.

PR₂₀ imparts direct inhibitory effects on the proteasome *in vitro*

Considering the major role of the proteasome in the degradation of ubiquitinated substrates, we focused on the effects of PR₂₀ on the UPS. PR₂₀ could impede UPS

flux in a variety of ways, such as: (1) reducing access of ubiquitylated substrates to the proteasome and their proper presentation by shuttle factors, (2) increasing deubiquitylation, (3) impeding transiting of substrates into the catalytic core of the proteasome, or (4) inhibiting proteolysis. To help distinguish among these possibilities, we began by asking whether PR₂₀ directly associates with proteasomes. Cell lysates from HEK293T cells engineered to express biotinylated proteasomes were incubated with PR₂₀ or GR₂₀. Avidin-coated beads were then used to purify proteasomes, and the pull-down material was subjected to immunoblotting. We find that PR₂₀, but not GR₂₀, associates with proteasomes in this assay and increasing the amounts of proteasomes leads to more pull-down of PR₂₀ (Fig. 6A). In light of this observation, we hypothesized that PR₂₀ directly inhibits proteasomal substrate degradation.

To investigate the mechanism of action of PR₂₀ on the proteasome, we turned to an *in vitro* system with pre-defined components. Incubation of purified proteasomes with a test substrate (Ub-Sic1) leads to time- and ATP-dependent degradation of Sic1 (Verma et al., 2001). Here, we preincubated proteasomes with PR₂₀ at various molar and subsequently followed the time-dependent degradation of Ub-Sic1 or PR₂₀.

Ub-Sic1 or PR₂₀ levels were determined at 0, 5, and 15 min after exposure to purified 26S proteasomes (Fig. 6B–D). In these experiments, we see a time-dependent loss of Ub-Sic1 and when PR₂₀ is added to these reactions. There is no change in the abundance of PR₂₀ or the alpha 3 subunit of the proteasome over time. Thus, with or without PR₂₀, we see specific degradation of Ub-Sic1 in this assay, but PR₂₀ is not itself degraded by the proteasome (Fig. 6B).

In the absence of PR₂₀, there is progressive reduction in Ub-Sic1 abundance, and quantification of signal shows experimental group differences by ANOVA ($F_{(2,9)} = 773.0$, $p < 0.001$). *Post hoc* analysis reveals statistically significantly less Ub-Sic1 at the 5- and 15-min time points in comparison with the starting level ($p < 0.001$ and $p < 0.001$). At a molar ratio of 1:10 or 1:100 (proteasomes: PR₂₀), there is also a progressive reduction in Ub-Sic1 abundance and quantification of signal shows experimental group differences by ANOVA ($F_{(2,9)} = 679.5$, $p < 0.001$) and $F_{(2,9)} = 762.6$, $p < 0.001$, respectively). *Post hoc* analysis reveals statistically significantly less Ub-Sic1 at the 5-min ($p < 0.01$ and $p < 0.01$) and 15-min ($p < 0.01$ and $p < 0.01$) time points in comparison with the starting level.

Qualitatively it appears, however, that the progressive reduction of Ub-Sic1 is less pronounced in the presence of PR₂₀. To quantify this, we monitored the difference between the Ub-Sic1 signal at the starting point versus the 5- or 15-min time point (e.g., Δ^{0-5} and Δ^{0-15}). We then compared the Δ^{0-5} of the three experimental groups (e.g., in the absence of PR₂₀, 1:10 proteasomes:PR₂₀ and 1:100 proteasomes:PR₂₀) and found group differences by ANOVA ($F_{(2,9)} = 32.42$, $p < 0.001$) (Fig. 6D). *Post hoc* analysis reveals statistically significant less Δ^{0-5} in the 1:10 and 1:100 experimental groups compared with the

Figure 6. PR₂₀, but not GR₂₀ binds to proteasomes; PR₂₀ inhibits the proteasomal degradation of a test substrate. **A**, By pulling down human proteasomes and then immunoblotting against HA, a direct association of PR₂₀ (but not GR₂₀) peptides to the proteasome is demonstrated. Increasing amounts of proteasome leads to more associated PR₂₀. Proteasomes are identified

continued

using an antibody recognizing the $\alpha 3$ subunit. **B**, Immunoblot images of Ub-Sic1, HA tag, and $\alpha 3$ loading controls. Molar ratios represent the ratio between 26S proteasomes (PTSM) and PR₂₀ peptides. The molar ratios of 1:0, 1:10, and 1:100 were each subject to proteasomal degradation of Ub-Sic1 for 0, 5, and 15 min. Time-dependent loss of Ub-Sic1 is noted. There is no change in the abundance of HA-tagged PR₂₀ or the $\alpha 3$ subunit. **C**, Quantification of Ub-Sic1 levels normalized to loading controls for each condition. Values represent means ($n = 3$), and the error bars represent SE. **D**, Quantification of the difference between starting level of Ub-Sic1 and Ub-Sic1 abundance at the 5- and 15-min time points. *, $p < 0.01$.

no PR₂₀ group ($p < 0.05$ and $p < 0.05$). Similarly, we compared the Δ^{0-15} of the three experimental groups and found group differences by ANOVA ($F_{(2,9)} = 8.667$, $p = 0.008$) (Fig. 6D). *Post hoc* analysis reveals statistically significantly less Δ^{0-15} in the 1:10 and 1:100 experimental group compared with the no PR₂₀ group ($p < 0.05$ and $p < 0.05$). Together, these observations suggest that PR₂₀ operates at the level of the proteasome to impede the function of the UPS. This observation is consistent with the hypothesis that PR₂₀ causes ubiquitylated substrate build-up due to impaired proteasome function.

Pharmacological inhibition of the proteasome is toxic to motor neurons, reduces flux of ubiquitylated substrates, and can be rescued by DUB inhibition

If PR₂₀ kills motor neurons by partial inhibition of the proteasome, then partial inhibition of the proteasome by pharmacological means might: (1) be toxic to motor neurons and, critically, (2) impair proteasomal flux to a similar degree as seen with PR₂₀. These predictions presuppose that proteasomal inhibition by PR₂₀ and by MG132 (for example) are equivalent in terms of pharmacodynamics, pharmacokinetics, and selectivity versus nonselectivity in ubiquitylated substrate build-up. We added varying concentrations of MG132 one time to our mixed spinal cord cultures and found an LD₅₀ of ~100–150 nM when motor neuron number was determined 5 d later (Fig. 7A). We then studied proteasomal flux by incubating sets of DIV14 cultures with 150 nM MG132 or vehicle for 48 h and then treating half of each set with 5 μ M MG132 or vehicle for 4 h before creating cell lysates and probing for ubiquitin (as described above in Figure 4). With $n = 6$ replicates in each experimental group, the permutation test found a statistically significant reduction in proteasomal flux in the 150 nM pretreatment group compared with the control ($p = 0.027$) (Fig. 7B,C). Finally, we asked whether proteasomal activation with the USP14 DUB inhibitor IU1 (Lee et al., 2010) could protect motor neurons from MG132 toxicity. Parallel sets of dishes were treated with 150 nM MG132 (or vehicle) and 5 μ M IU1 (or vehicle). Counts of motor neurons 5 d later revealed statistically significant group differences by ANOVA ($F_{(8,119)} = 5.924$, $p < 0.001$). The *post hoc* analysis revealed statistically significantly fewer motor neurons in the MG132-treated group in comparison with all other experimental groups ($p = 0.001$). No other group differences were found (Fig. 7D). Thus, pharmacological inhibition of the proteasome that achieves a reduc-

Figure 7. MG132 is toxic to motor neurons, inhibits flux through the proteasome, and cell death is rescued by the DUB inhibitor IU1. MG132 was applied one time at varying concentrations to mixed spinal cord cultures and 5 d later processed for immuno-

continued

cytochemical quantification of motor neurons. **A**, The dose-response curve shows that MG132 kills motor neurons with an LD₅₀ of ~ 100–150 nM. **B**, Mixed spinal cord cultures were exposed to 150 nM MG132 or vehicle for 48 h, and the parallel groups of cultures were exposed to 5 μ M MG132 or vehicle for 4 h. Cell lysates were prepared and blotted for total ubiquitin levels. The difference of the ubiquitin immunoreactivity in the cultures treated with 5 μ M or vehicle reports the flux of substrates through the UPS over 4 h. Representative blots are shown. **C**, Quantification of the data from the flux assay and statistical analysis by the permutation tests reveals a statistically significant inhibition of flux through the UPS in cultures treated with 150 nM for 48 h ($p = 0.027$). **D**, Number of motor neuron in mixed spinal cord cultures after exposure of 150 nM MG132 or vehicle and 5 μ M IU1 or vehicle. MG132 leads to a statistically significant reduction in motor neuron number, and this is reversed by IU1 treatment. IU1 alone is not toxic.

tion influx equivalent to PR₂₀ evokes motor neuron death. This observation supports the view that the toxic activity of PR₂₀ could be mediated by proteasomal inhibition; a notion reinforced by the observation that stimulation of the proteasome protects against this level of proteasomal flux inhibition.

Induction of the proteasome rescues neuronal survival in the presence of PR₂₀

Finally, we asked whether IU1 protects against PR₂₀-induced motor neuron death. We applied PR₂₀ (or vehicle) and IU1 (or vehicle) to cultures and quantified the number of motor neurons alive after 5 d of treatment with each condition (Fig. 8). Statistically significant group differ-

Figure 8. PR₂₀-evoked motor neuron death is prevented by the proteasome activator, IU1. Mixed spinal cord cultures were exposed to PR₂₀ or vehicle and then dosed with IU1 or vehicle. Motor neuron number was determined 5 d later. In the absence of PR₂₀, IU1 did not affect motor neuron survival. PR₂₀ treatment leads to approximately 50% loss of motor neurons and IU1 application prevents this effect. n.s., not significant; *, $p < 0.05$.

ences were found by ANOVA ($F_{(8,132)} = 7.408, p < 0.001$). The *post hoc* analysis indicated that a statistically significant decrease in motor neuron survival occurs in the presence of PR₂₀ and this is rescued to control levels upon treatment with IU1 ($p < 0.05$). IU1 did not influence the survival of vehicle-treated cells. This suggests that the PR₂₀-mediated proteasomal degradation dysfunction plays a role in the lethality that the dipeptide imparts on cells.

Discussion

The mechanism by which C9ORF72 HRE mutations cause ALS/frontotemporal dementia (FTD) (Renton et al., 2011) is an active area of inquiry. Evidence exists for both a toxic RNA gain-of-function and for the production of toxic DPR proteins (Haeusler et al., 2014; Mizielińska et al., 2014). In an effort to distinguish between the contributions of RNA versus that of DPR proteins, we studied the effects of synthetic dipeptides on mixed cultures. We find that PR₂₀ is taken up by neurons and astrocytes and disrupts both the UPS and the autophagic protein degradation pathways. GR₂₀, however, did not have an effect on the UPS. PR₂₀ has a direct inhibitory effect upon the proteasome when tested *in vitro*. It is likely that these effects of PR₂₀ are pathophysiological since pharmacological stimulation of the proteasome promotes motor neuron survival in the presence of PR₂₀. The effects of PR₂₀ appear molecularly distinct from mTDP43- or mSOD-mediated toxicity (Betz and Hall, 2013; Saxena et al., 2013; Perera et al., 2014; Kong and Xu, 1998). Our results suggest a specific mechanism by which proline/arginine DPR proteins are injurious to motor neurons. Since DPR peptides are seen in human autopsy tissues (Ash et al., 2013; Mori et al., 2013), our *in vitro* observations have implications for human disease.

Among the technical considerations inherent in all disease models, we feel that three merit special discussion. First, many of our experiments are performed after adding PR₂₀ to the culture media, achieving an extracellular concentration of 2 μ M. What intracellular concentration of PR₂₀ does this translate into, does it vary over time and/or by cell-type, and most importantly, how do these values compare to the concentration of cellular DPR proteins generated in other experimental platforms? There are no good data on these difficult questions. It is noteworthy that many investigators have deployed the CMV or CAGG promoters to drive high DPR protein expression from an engineered cDNA (Wen et al., 2014; Zhang et al., 2014; Yamakawa et al., 2015). Unfortunately, we lack the quantitative data on the cellular concentration of RAN peptides in these models that could form the basis of comparison with our results. Second, when using purified proteasomes and a ubiquitylated test substrate *in vitro* (e.g., Ub-Sic1) to determine proteasomal degradation rate, is the PR₂₀-dependent inhibition of the proteasome reporting a physiological event? This is a valid concern, since we only see the PR₂₀ effect when the molar ratio of PR₂₀ to proteasomes is 10:1 or greater. The protein concentration in our *in vitro* reaction is 20 nM, and it is not possible to substantially increase the concentration because the

proteins no longer remain soluble. On the other hand, estimates of protein concentrations in cells are about 0.25 g/ml [which for 100-kDa proteins is roughly equivalent to 5 mM (Milo, 2013)], ~5 orders of magnitude greater than that which can be achieved *in vitro*. The biology of RAN peptides and proteasomes in the crowded environment of cells can, at best, be approximated by *in vitro* assays, although synthetic PR₂₀ and purified human proteasomes directly interact with each other. Whether the 10:1 ratio is truly reporting on events occurring *in vitro* will ultimately depend on its predictive value. In light of all of the data we have assembled, we think a reasonable case can be made that the Ub-Sic1/proteasome/PR₂₀ observations are valid and relevant. Third, when DPR proteins are expressed from a cDNA, 36 repeat products (Mizielinska et al., 2014; Tran et al., 2015), 42 repeat products (Wen et al., 2014), 50 repeat products (Zhang et al., 2014), 66 repeat products (Kramer et al., 2016), and 100 repeat products (Yamakawa et al., 2015) are toxic. The extent to which cognate cDNAs are translated to generate the intended full-length product is unclear. In addition, the length of DPRs that are benign and the length beyond which toxicity is detectable remains murky. The selection of 20 repeats of PR or GR in our study was based on the observations of others that this length of DPR can be toxic (Kwon et al., 2014; Kanekura et al., 2016). DPRs as short as 6 repeats (such as GR₆ and GA₆) can be toxic to neurons; we do not know whether PR₆ is toxic and if so, whether this involves the proteasome (Flores et al., 2016). Future studies should investigate these issues as well as determine the prevalence of DPRs of specific lengths in human cells with HRE C9ORF72.

In an attempt to distinguish the effects of toxic mRNA species from those of DPR proteins, many research groups have taken advantage of the degeneracy in the genetic code to create DPR proteins in the absence of GGGGCC repeats. Whether the cognate mRNA by itself is truly nontoxic remains, in our opinion, an open question. G-C-rich RNAs can adopt a variety of secondary structures even without long, uninterrupted stretches of GGGGCC that could attract and sequester RNA-binding proteins. We believe that studies in which cognate RNA is translated to create DPR proteins do not exclude the possibility of RNA toxicity and thus should be interpreted with caution. Only a few groups have studied the effects of synthetic DPR peptides (unambiguously excluding the contribution of mRNA toxicity in models of C9ORF72 HRE toxicity) (Kwon et al., 2014; Chang et al., 2016; Kanekura et al., 2016), and only one studied primary neurons (Flores et al., 2016).

Notwithstanding the above concerns using translation of non-GGGGCC constructs to generate diaminic acid peptide, many groups have investigated the toxicities of various DPR proteins. Wen et al. (2014) showed that PR_n is toxic in primary cortical and motor neuron cultures, and Mizielinska et al. (2014) and Wen et al. (2014) found that PR_n and GR_n, but not PA_n and GA_n, are toxic in a fly model. In primary neuron cultures, GA_n and GR_n are toxic (May et al., 2014; Zhang et al., 2014; Flores et al., 2016), and this can be associated with ER stress and cytoplas-

mic/nuclear inclusions. Joviči et al. (2015) also showed PR_n, PA_n, and GR_n are toxic in a yeast model. Recently described mouse work adds further interpretive difficulties. O'Rourke et al. (2015) showed that GA_n and GP_n dipeptides accumulated in a bacterial artificial chromosome transgenic mouse model but were not associated with phenotypic changes to mouse behavior or neurodegeneration. On the other hand, Yamakawa et al. (2015) found GA_n linked behavioral deficits using *in utero* electroporation in mice to express the dipeptides in the cerebral cortex. In sum, while there is no question that DPR proteins are present in patients and in various disease models, precisely which species are toxic (or the extent to which they are toxic) remains contentious.

We, and others (Kwon et al., 2014), have found that PR₂₀ accumulates in the nucleus, raising the interesting prospect that inhibition of nuclear proteasomes underlies the pathophysiology. Protein quality control (PQC) pathways manage misfolded proteins within distinct subcellular compartments (Shibata and Morimoto, 2014). There is a rich literature about PQC in the ER and cytoplasm, but less is known about PQC in the nucleus. The UPS is the main mechanism for protein degradation in the nucleus (Jones and Gardner, 2016; Gallagher et al., 2014; Shibata and Morimoto, 2014) and the nucleus harbors the majority of cellular proteasomes (Wójcik and DeMartino, 2003; although see Dang et al., 2016). In yeast, the San1 ubiquitin ligase targets misfolded nuclear proteins for proteasomal degradation (Gardner et al., 2005; Rosenbaum et al., 2011). Other ubiquitin ligases implicated in nuclear PQC include Ubr1, Doa10, and Asi, others are likely to exist (Jones and Gardner, 2016). In addition to targeting misfolded nuclear proteins, some cytosolic proteins (i.e., polyQ-expanded proteins) are imported into the nucleus for degradation (Park et al., 2013). The features of damaged cytosolic proteins that identify them for nuclear import and disposal by the nuclear PQC pathway are unknown. PR₂₀ inhibition of nuclear proteasomes could have broad effects not only on the integrity of the nuclear proteome but also on interconnected PQC pathways in other subcellular domains.

In various disease model platforms, HRE RNA foci and DPR protein puncta have been demonstrated. Our understanding of how these entities are linked to cell dysfunction and death is inchoate. Additionally, defects in nucleocytoplasmic shuttling, ER stress, proteasomal dysfunction, and nucleolar stress have also been described in various models. However, a detailed connection of these processes gone awry and disease pathogenesis is not well understood (Kwon et al., 2014; Wen et al., 2014; Freibaum et al., 2015; Joviči et al., 2015; Yamakawa et al., 2015; Zhang et al., 2015; Zhang et al., 2016).

Here, we show that PR₂₀ dipeptides kill motor neurons and lead to a time-dependent build-up of ubiquitylated substrates, an effect we ascribed to an impairment of both the UPS and autophagy pathways. PR₂₀ physically associated with the proteasome and we suggest that this interaction underlies the functional impairment of the UPS. That another RAN translation product, GR₂₀, is neither toxic to motor neurons nor leads to impairment in

UPS flux, highlights the specificity of the proposed molecular mechanism for PR₂₀ toxicity. To understand why the accumulation of ubiquitylated substrates is toxic, it will be important to determine which ubiquitylated substrates accumulate in the presence of PR₂₀. Two broad possibilities exist: (1) PR₂₀ may nonspecifically inhibit the degradation of ubiquitylated substrates, and this could be toxic owing to the accumulation of damaged/misfolded proteins; or (2) PR₂₀ may inhibit the degradation of a specific subset of ubiquitylated substrates, and this could be toxic owing to the disruption of a select cell biological process. Resolving the contributions of these alternative possibilities may provide mechanistic insight into the pathophysiology.

References

- Aiken CT, Kaake RM, Wang X, Huang L (2011) Oxidative stress-mediated regulation of proteasome complexes. *Mol Cell Proteomics* 10:R110.006924. [CrossRef](#)
- Al-Sarraj S, King A, Troakes C, Smith B, Maekawa S, Bodi I, Rogelj B, Al-Chalabi A, Hortobágyi T, Shaw CE (2011) p62 positive, TDP-43 negative, neuronal cytoplasmic and intranuclear inclusions in the cerebellum and hippocampus define the pathology of C9ORF72-linked FTL and MND/ALS. *Acta Neuropathol* 122:691–702. [CrossRef](#)
- Arrasate M, Mitra S, Schweitzer ES, Segal MR, Finkbeiner S (2004) Inclusion body formation reduces levels of mutant huntingtin and the risk of neuronal death. *Nature* 431:805–810. [CrossRef](#)
- Ash PEA, Bieniek KF, Gendron TF, Caulfield T, Lin WL, DeJesus-Hernandez M, ... Petrucelli L (2013) Unconventional translation of C9ORF72 GGGGCC expansion generates insoluble polypeptides specific to c9FTD/ALS. *Neuron* 77:639–646. [CrossRef](#)
- Baldin V, Militello M, Thomas Y, Doucet C, Fic W, Boireau S, Jariel-Encontre I, Piechaczyk M, Bertrand E, Tazi J, Coux O (2008) A novel role for PA28 γ -proteasome in nuclear speckle organization and SR protein trafficking. *Mol Biol Cell* 19:1706–1716. [CrossRef](#)
- Bao W, Gu Y, Ta L, Wang K, Xu Z (2016) Induction of autophagy by the MG132 proteasome inhibitor is associated with endoplasmic reticulum stress in MCF7 cells. *Mol Med Rep* 13:796–804. [CrossRef](#)
- Barber SC, Mead RJ, Shaw PJ (2006) Oxidative stress in ALS: a mechanism of neurodegeneration and a therapeutic target. *Biochim Biophys Acta* 1762:1051–1067. [CrossRef](#) [Medline](#)
- Barmada SJ, Serio A, Arjun A, Bilican B, Daub A, Ando DM, Tsvetkov A, Pleiss M, Li X, Peisach D, Shaw C, Chandran S, Finkbeiner S (2014) Autophagy induction enhances TDP43 turnover and survival in neuronal ALS models. *Nat Chem Biol* 10:677–685. [CrossRef](#) [Medline](#)
- Bence NF, Sampat RM, Kopito RR (2001) Impairment of the ubiquitin-proteasome system by protein aggregation. *Science* 292:1552–1555. [CrossRef](#)
- Betz C, Hall MN (2013) Where is mTOR and what is it doing there? *J Cell Biol* 203:563–574. [CrossRef](#) [Medline](#)
- Boeynaems S, Bogaert E, Michiels E, Gijssels I, Sieben A, Joviči A, De Baets G, Scheveneels W, Steyaert J, Cuijt I, Verstrepen KJ, Callaerts P, Rousseau F, Schymkowitz J, Cruts M, Van Broeckhoven C, Van Damme P, Gitler AD, Robberecht W, Van Den Bosch L (2016) Drosophila screen connects nuclear transport genes to DPR pathology in c9ALS/FTD. *Sci Rep* 6:20877. [CrossRef](#) [Medline](#)
- Cheng Y, Ren X, Hait WN, Yang JM (2013) Therapeutic targeting of autophagy in disease: biology and pharmacology. *Pharmacol Rev* 65:1162–1197. [CrossRef](#)
- Chang YJ, Jeng US, Chiang YL, Hwang IS, Chen YR (2016) Glycine-alanine dipeptide repeat from C9ORF72 hexanucleotide expansions forms toxic amyloids possessing cell-to-cell transmission property. *J Biol Chem* 291:4903–4911. [CrossRef](#)
- Conlon EG, Lu L, Sharma A, Yamazaki T, Tang T, Shneider NA, Manley JL (2016) The C9ORF72 GGGGCC expansion forms RNA G-quadruplex inclusions and sequesters hnRNP H to disrupt splicing in ALS brains. *eLife* 5:345. [CrossRef](#)
- Choi WH, de Poot SAH, Lee JH, Kim JH, Han DH, Kim YK, Finley D, Lee MJ (2016) Open-gate mutants of the mammalian proteasome show enhanced ubiquitin-conjugate degradation. *Nat Commun* 7:10963. [CrossRef](#)
- Chudakov DM, Lukyanov S, Lukyanov KA (2007) Tracking intracellular protein movements using photoswitchable fluorescent proteins PS-CFP2 and Dendra2. *Nat Protoc* 2:2024–2032. [CrossRef](#)
- Dang FW, Chen L, Madura K (2016) Catalytically active proteasomes function predominantly in the cytosol. *J Biol Chem* 291:18765–18777. [CrossRef](#)
- DeJesus-Hernandez M, Mackenzie IR, Boeve BF, Boxer AL, Baker M, Rutherford NJ, Nicholson AM, Finch NA, Flynn H, Adamson J, Kouri N, Wojtas A, Sengdy P, Hsiung GY, Karydas A, Seeley WW, Josephs KA, Coppola G, Geschwind DH, Wszolek ZK, Feldman H, et al. (2011) Expanded GGGGCC hexanucleotide repeat in non-coding region of C9ORF72 causes chromosome 9p-linked FTD and ALS. *Neuron* 72:245–256. [CrossRef](#)
- Ding WX, Ni HM, Gao W, Yoshimori T, Stolz DB, Ron D, Yin XM (2007) Linking of autophagy to ubiquitin-proteasome system is important for the regulation of endoplasmic reticulum stress and cell viability. *Am J Pathol* 171:513–524. [CrossRef](#)
- Fingar DC, Richardson CJ, Tee AR, Cheatham L, Tsou C, Blenis J (2004) mTOR controls cell cycle progression through its cell growth effectors S6K1 and 4E-BP1/eukaryotic translation initiation factor 4E. *Mol Cell Biol* 24:200–216. [CrossRef](#)
- Flores BN, Dulchavsky ME, Krans A, Sawaya MR, Paulson HL, Todd PK, et al. (2016) Distinct C9orf72-associated dipeptide repeat structures correlate with neuronal toxicity. *PLoS One* 11:e0165084. [CrossRef](#)
- Freibaum BD, Lu Y, Lopez-Gonzalez R, Kim NC, Almeida S, Lee KH, Badders N, Valentine M, Miller BL, Wong PC, Petrucelli L, Kim H, Gao FB, Taylor JP (2015) GGGGCC repeat expansion in C9ORF72 compromises nucleocytoplasmic transport. *Nature* 525:129–133. [CrossRef](#)
- Gallagher PS, Oeser ML, Abraham AC, Kaganovich D, Gardner RG (2014) Cellular maintenance of nuclear protein homeostasis. *Cell Mol Life Sci* 71:1865–1879. [CrossRef](#) [Medline](#)
- Gardner RG, Nelson ZW, Gottschling DE (2005) Degradation-mediated protein quality control in the nucleus. *Cell* 120:803–815. [CrossRef](#) [Medline](#)
- Gitler AD, Tsuiji H (2016) There has been an awakening: emerging mechanisms of C9ORF72 mutations in FTD/ALS. *Brain Res* 1647:19–29. [CrossRef](#)
- Glick D, Barth S, Macleod KF (2010) Autophagy: cellular and molecular mechanisms. *J Pathol* 221:3–12. [CrossRef](#) [Medline](#)
- Glickman MH, Ciechanover A (2002) The ubiquitin-proteasome proteolytic pathway: destruction for the sake of construction. *Physiol Rev* 82:373–428. [CrossRef](#)
- Goldberg AL (2012) Development of proteasome inhibitors as research tools and cancer drugs. *J Cell Biol* 199:583–588. [CrossRef](#) [Medline](#)
- Gubbens J, Ruijter E, de Fays LEV, Damen JMA, de Kruijff B, Slijper M, Rijkers DT, Liskamp RM, de Kroon AI (2009) Photocrosslinking and click chemistry enable the specific detection of proteins interacting with phospholipids at the membrane interface. *Chem Biol* 16:3–14. [CrossRef](#)
- Haeusler AR, Donnelly CJ, Periz G, Simko EAJ, Shaw PG, Kim MS, Maragakis NJ, Troncoso JC, Pandey A, Sattler R, Rothstein JD, Wang J (2014) C9ORF72 nucleotide repeat structures initiate molecular cascades of disease. *Nature* 507:195–200. [CrossRef](#)
- Jones RD, Gardner RG (2016) Protein quality control in the nucleus. *Curr Opin Cell Biol* 40:81–89. [CrossRef](#) [Medline](#)
- Joviči A, Mertens J, Boeynaems S, Bogaert E, Chai N, Yamada SB, Paul JW 3rd, Sun S, Herdy JR, Bieri G, Kramer NJ, Gage FH, Van Den Bosch L, Robberecht W, Gitler AD (2015) Modifiers of C9ORF72 dipeptide repeat toxicity connect nucleocytoplasmic

- transport defects to FTD/ALS. *Nat Neurosci* 18:1226–1229. [CrossRef](#)
- Joyce PI, Fratta P, Fisher EMC, Acevedo-Arozena A (2011) SOD1 and TDP-43 animal models of amyotrophic lateral sclerosis: recent advances in understanding disease toward the development of clinical treatments. *Mamm Genome* 22:420–448. [CrossRef](#)
- Kabashi E, Agar JN, Strong MJ, Durham HD (2012) Impaired proteasome function in sporadic amyotrophic lateral sclerosis. *Amyotroph Lateral Scler* 13:367–371. [CrossRef](#)
- Kanekura K, Yagi T, Cammack AJ, Mahadevan J, Kuroda M, Harms MB, Miller TM, Urano F (2016) Poly-dipeptides encoded by the C9ORF72 repeats block global protein translation. *Hum Mol Genet* 25:1803–1813. [CrossRef](#)
- Kaufman RJ (1999) Stress signaling from the lumen of the endoplasmic reticulum: coordination of gene transcriptional and translational controls. *Genes Dev* 13:1211–1233. [CrossRef](#)
- Kiernan MC, Vucic S, Cheah BC, Turner MR, Eisen A, Hardiman O, Burrell JR, Zoing MC (2011) Amyotrophic lateral sclerosis. *Lancet* 377:942–955. [CrossRef](#) [Medline](#)
- Klionsky DJ, Abdalla FC, Abeliovich H, Abraham RT, Acevedo-Arozena A, Adeli K, Agholme L, Agnello M, Agostinis P, Aguirre-Ghiso JA, Ahn HJ, Ait-Mohamed O, Ait-Si-Ali S, Akematsu T, Akira S, Al-Younes HM, Al-Zeer MA, Albert ML, Albin RL, Alegre-Abarategui J, et al. (2012) Guidelines for the use and interpretation of assays for monitoring autophagy. *Autophagy* 8:445–544. [Medline](#)
- Klionsky DJ, Abdelmohsen K, Abe A, Abedin MJ, Abeliovich H, Acevedo Arozena A, Adachi H, Adams CM, Adams PD, Adeli K, Adihetty PJ, Adler SG, Agam G, Agarwal R, Aghi MK, Agnello M, Agostinis P, Aguilar PV, Aguirre-Ghiso J, Airolidi EM, et al. (2016) Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition). *Autophagy* 12:1–222. [CrossRef](#) [Medline](#)
- Koga H, Martinez-Vicente M, Macian F, Verkhusha VV, Cuervo AM (2011) A photoconvertible fluorescent reporter to track chaperone-mediated autophagy. *Nat Commun* 2:386. [CrossRef](#)
- Kong J, Xu Z (1998) Massive mitochondrial degeneration in motor neurons triggers the onset of amyotrophic lateral sclerosis in mice expressing a mutant SOD1. *J Neurosci* 18:3241–3250.
- Kramer NJ, Carlomagno Y, Zhang YJ, Almeida S, Cook CN, Gendron TF, et al. (2016) Spt4 selectively regulates the expression of C9ORF72 sense and antisense mutant transcripts. *Science* 353:708–712. [CrossRef](#) [Medline](#)
- Kwon I, Xiang S, Kato M, Wu L, Theodoropoulos P, Wang T, Kim J, Yun J, Xie Y, McKnight SL (2014) Poly-dipeptides encoded by the C9ORF72 repeats bind nucleoli, impede RNA biogenesis, and kill cells. *Science* 345:1139–1145. [CrossRef](#) [Medline](#)
- Lan D, Wang W, Zhuang J, Zhao Z (2015) Proteasome inhibitor-induced autophagy in PC12 cells overexpressing A53T mutant α -synuclein. *Mol Med Res* 11:1655–1660. [CrossRef](#)
- Lecker SH, Goldberg AL, Mitch WE (2006) Protein degradation by the ubiquitin–proteasome pathway in normal and disease states. *J Am Soc Nephrol* 17:1807–1819. [CrossRef](#)
- Lee BH, Lee MJ, Park S, Oh DC, Elsasser S, Chen PC, Gartner C, Dimova N, Hanna J, Gygi SP, Wilson SM, King RW, Finley D (2010) Enhancement of proteasome activity by a small-molecule inhibitor of USP14. *Nature* 467:179–184. [CrossRef](#) [Medline](#)
- Lee KH, Zhang P, Kim HJ, Mitrea DM, Sarkar M, Freibaum BD, Cika J, Coughlin M, Messing J, Molliex A, Maxwell BA, Kim NC, Temirov J, Moore J, Kolaitis RM, Shaw TI, Bai B, Peng J, Kriwacki RW, Taylor JP (2016) C9ORF72 dipeptide repeats impair the assembly, dynamics, and function of membrane-less organelles. *Cell* 167:774–788.e17. [CrossRef](#) [Medline](#)
- Li J, McCullough LD (2010) Effects of AMP-activated protein kinase in cerebral ischemia. *J Cereb Blood Flow Metab* 30:480–492. [CrossRef](#) [Medline](#)
- Lilienbaum A (2013) Relationship between the proteasomal system and autophagy. *Int J Biochem Mol Biol* 4:1–26. [Medline](#)
- Lim MA, Selak MA, Xiang Z, Krainc D, Neve RL, Kraemer BC, Watts JL, Kalb RG (2012) Reduced activity of AMP-activated protein kinase protects against genetic models of motor neuron disease. *J Neurosci* 32:1123–1141. [CrossRef](#)
- Lin Y, Mori E, Kato M, Xiang S, Wu L, Kwon I, McKnight SL (2016) Toxic PR poly-dipeptides encoded by the C9ORF72 repeat expansion target LC domain polymers. *Cell* 167:789–802.e12. [CrossRef](#) [Medline](#)
- Ling SC, Polymenidou M, Cleveland DW (2013) Converging mechanisms in ALS and FTD: disrupted RNA and protein homeostasis. *Neuron* 79:416–438. [CrossRef](#) [Medline](#)
- Loos B, du Toit A, Hofmeyr JHS (2014) Defining and measuring autophagosome flux—concept and reality. *Autophagy* 10:2087–2096. [CrossRef](#) [Medline](#)
- May S, Hornburg D, Schludi MH, Arzberger T, Rentzsch K, Schwenk BM, Grässer FA, Mori K, Kremmer E, Banzhaf-Strathmann J, Mann M, Meissner F, Edbauer D (2014) C9ORF72 FTL/ALS-associated Gly-Ala dipeptide repeat proteins cause neuronal toxicity and Unc119 sequestration. *Acta Neuropathol* 128:485–503. [CrossRef](#) [Medline](#)
- Meyer AJ, Brach T, Marty L, Kreye S, Rouhier N, Jacquot JP, Hell R (2007) Redox-sensitive GFP in *Arabidopsis thaliana* is a quantitative biosensor for the redox potential of the cellular glutathione redox buffer. *Plant J* 52:973–986. [CrossRef](#)
- Milo R (2013) What is the total number of protein molecules per cell volume? A call to rethink some published values. *BioEssays* 35:1050–1055. [CrossRef](#)
- Mizielinska S, Grönke S, Niccoli T, Ridler CE, Clayton EL, Devoy A, Moens T, Norona FE, Woollacott IO, Pietrzyk J, Cleverley K, Nicoll AJ, Pickering-Brown S, Dols J, Cabecinha M, Hendrich O, Fratta P, Fisher EM, Partridge L, Isaacs AM (2014) C9ORF72 repeat expansions cause neurodegeneration in *Drosophila* through arginine-rich proteins. *Science* 345:1192–1194. [CrossRef](#)
- Mizushima N, Yoshimori T, Levine B (2010) Methods in mammalian autophagy research. *Cell* 140:313–326. [CrossRef](#) [Medline](#)
- Mojsilovic-Petrovic J, Jeong GB, Crocker A, Arneja A, David S, Russell D, Kalb RG (2006) Protecting motor neurons from toxic insult by antagonism of adenosine A2a and Trk receptors. *J Neurosci* 26:9250–9263. [CrossRef](#)
- Mori K, Weng SM, Arzberger T, May S, Rentzsch K, Kremmer E, Schmid B, Kretschmar HA, Cruts M, Van Broeckhoven C, Haass C, Edbauer D (2013) The C9ORF72 GGGGCC repeat is translated into aggregating dipeptide-repeat proteins in FTL/ALS. *Science* 339:1335–1338. [CrossRef](#) [Medline](#)
- O'Rourke JG, Bogdanik L, Muhammad AKMG, Gendron TF, Kim KJ, Austin A, Cady J, Liu EY, Zarrow J, Grant S, Ho R, Bell S, Carmona S, Simpkinson M, Lall D, Wu K, Daugherty L, Dickson DW, Harms MB, Petrucelli L, et al. (2015) C9ORF72 BAC transgenic mice display typical pathologic features of ALS/FTD. *Neuron* 88:892–901. [CrossRef](#)
- Park SH, Kukushkin Y, Gupta R, Chen T, Konagai A, Hipp MS, Hayer-Hartl M, Hartl FU (2013) PolyQ proteins interfere with nuclear degradation of cytosolic proteins by sequestering the Sis1p chaperone. *Cell* 154:134–145. [CrossRef](#) [Medline](#)
- Pearson CE (2011) Repeat associated non-ATG translation initiation: one DNA, two transcripts, seven reading frames, potentially nine toxic entities! *PLoS Genet* 7:e1002018. [CrossRef](#)
- Perera ND, Sheehan RK, Scott JW, Kemp BE, Horne MK, Turner BJ (2014) Mutant TDP-43 deregulates AMPK activation by PP2A in ALS models. *PLoS One* 9:e90449. [CrossRef](#) [Medline](#)
- Renton AE, Majounie E, Waite A, Simón-Sánchez J, Rollinson S, Gibbs JR, Schymick JC, Laaksovirta H, van Swieten JC, Myllykangas L, Kalimo H, Paetau A, Abramzon Y, Remes AM, Kaganovich A, Scholz SW, Duckworth J, Ding J, Harmer DW, Hernandez DG, et al. (2011) A hexanucleotide repeat expansion in C9ORF72 is the cause of chromosome 9p21-linked ALS-FTD. *Neuron* 72:257–268. [CrossRef](#)
- Rivett AJ, Palmer A, Knecht E (1992) Electron microscopic localization of the multicatalytic proteinase complex in rat liver and in cultured cells. *J Histochem Cytochem* 40:1165–1172. [CrossRef](#)
- Rosen DR, Siddique T, Patterson D, Figlewicz DA, Sapp P, Hentati A, Donaldson D, Goto J, O'Regan JP, Deng HX, et al. (1993) Muta-

- tions in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis. *Nature* 362:59–62. [CrossRef](#)
- Rosenbaum JC, Fredrickson EK, Oeser ML, Garrett-Engle CM, Locke MN, Richardson LA, Nelson ZW, Hetrick ED, Milac TI, Gottschling DE, Gardner RG (2011) Disorder targets disorder in nuclear quality control degradation: a disordered ubiquitin ligase directly recognizes its misfolded substrates. *Mol Cell* 41:93–106. [CrossRef](#)
- Rowland LP, Shneider NA (2001) Amyotrophic lateral sclerosis. *N Engl J Med* 344:1688–1700. [CrossRef](#) [Medline](#)
- Rutherford NJ, Heckman MG, DeJesus-Hernandez M, Baker MC, Soto-Ortolaza AI, Rayaprolu S, Stewart H, Finger E, Volkening K, Seeley WW, Hatanpaa KJ, Lomen-Hoerth C, Kertesz A, Bigio EH, Lippa C, Knopman DS, Kretschmar HA, Neumann M, Caselli RJ, White CL 3rd, et al. (2012) Length of normal alleles of C9ORF72 GGGGCC repeat do not influence disease phenotype. *Neurobiol Aging* 33:2950.e5–2950.e7. [CrossRef](#)
- Saxena S, Roselli F, Singh K, Leptien K, Julien JP, Gros-Louis F, Caroni P (2013) Neuroprotection through excitability and mTOR required in ALS motoneurons to delay disease and extend survival. *Neuron* 80:80–96. [CrossRef](#)
- Shibata Y, Morimoto RI (2014) How the nucleus copes with proteotoxic stress. *Curr Biol* 24:R463–R474. [CrossRef](#) [Medline](#)
- Tanida I, Ueno T, Kominami E (2008). LC3 and autophagy. In: *Autophagosome and phagosome* (Deretic V, ed), pp 77–88. Totowa, NJ: Humana Press. Retrieved from [CrossRef](#)
- Tran H, Almeida S, Moore J, Gendron TF, Chalasani U, Lu Y, et al. (2015) Differential toxicity of nuclear RNA foci versus dipeptide repeat proteins in a Drosophila model of C9ORF72 FTD/ALS. *Neuron* 87:1207–1214. [CrossRef](#)
- Tsvetkov AS, Arrasate M, Barmada S, Ando DM, Sharma P, Shaby BA, Finkbeiner S (2013) Proteostasis of polyglutamine varies among neurons and predicts neurodegeneration. *Nat Chem Biol* 9:586–592. [CrossRef](#) [Medline](#)
- Verma R, McDonald H, Yates JR, III, Deshaies RJ (2001) Selective degradation of ubiquitinated Sic1 by purified 26S proteasome yields active S phase cyclin-Cdk. *Mol Cell* 8:439–448. [CrossRef](#) [Medline](#)
- Vilchez D, Saez I, Dillin A (2014) The role of protein clearance mechanisms in organismal ageing and age-related diseases. *Nat Commun* 5: 5659. Retrieved from [CrossRef](#)
- Vitale A, Denecke J (1999) The endoplasmic reticulum—gateway of the secretory pathway. *Plant Cell* 11:615–628. [CrossRef](#) [Medline](#)
- Wen X, Tan W, Westergard T, Krishnamurthy K, Markandiah SS, Shi Y, Lin S, Shneider NA, Monaghan J, Pandey UB, Pasinelli P, Ichida JK, Trotti D (2014a) Antisense proline-arginine RAN dipeptides linked to C9ORF72-ALS/FTD form toxic nuclear aggregates that initiate in vitro and in vivo neuronal death. *Neuron* 84:1213–1225. [CrossRef](#)
- Westergard T, Jensen BK, Wen X, Cai J, Kropf E, Iacovitti L, et al. (2016) Cell-to-cell transmission of dipeptide repeat proteins linked to C9ORF72-ALS/FTD. *Cell Rep* 17:645–652. [CrossRef](#) [Medline](#)
- Wijesekera L, Leigh PN (2009) Amyotrophic lateral sclerosis. *Orphanet J Rare Dis* 4:3. [CrossRef](#)
- Wójcik C, DeMartino GN (2003) Intracellular localization of proteasomes. *Int J Biochem Cell* 35:579–589.
- Yamakawa M, Ito D, Honda T, Kubo K, Noda M, Nakajima K, Suzuki N (2015) Characterization of the dipeptide repeat protein in the molecular pathogenesis of c9FTD/ALS. *Hum Mol Genet* 24:1630–1645. [CrossRef](#) [Medline](#)
- Zhai J, Zhang L, Mojsilovic-Petrovic J, Jian X, Thomas J, Homma K, Schmitz A, Famulok M, Ichijo H, Argon Y, Randazzo PA, Kalb RG (2015) Inhibition of cytoskeletons protects against genetic models of motor neuron disease. *J Neurosci* 35:9088–9105. [CrossRef](#) [Medline](#)
- Zhang K, Donnelly CJ, Haeusler AR, Grima JC, Machamer JB, Steinwald P, Daley EL, Miller SJ, Cunningham KM, Vidensky S, Gupta S, Thomas MA, Hong I, Chiu SL, Haganir RL, Ostrow LW, Matunis MJ, Wang J, Sattler R, Lloyd TE, et al. (2015) The C9ORF72 repeat expansion disrupts nucleocytoplasmic transport. *Nature* 525:56–61. [CrossRef](#)
- Zhang YJ, Gendron TF, Grima JC, Sasaguri H, Jansen-West K, Xu YF, Katzman RB, Gass J, Murray ME, Shinohara M, Lin WL, Garrett A, Stankowski JN, Daugherty L, Tong J, Perkerson EA, Yue M, Chew J, Castaneda-Casey M, Kurti A, et al. (2016) C9ORF72 poly(GA) aggregates sequester and impair HR23 and nucleocytoplasmic transport proteins. *Nat Neurosci* 19:668–677. [CrossRef](#) [Medline](#)
- Zhang YJ, Jansen-West K, Xu YF, Gendron TF, Bieniek KF, Lin WL, Sasaguri H, Caulfield T, Hubbard J, Daugherty L, Chew J, Belzil VV, Prudencio M, Stankowski JN, Castaneda-Casey M, Whitelaw E, Ash PE, DeTure M, Rademakers R, Boylan KB, et al. (2014) Aggregation-prone c9FTD/ALS poly(GA) RAN-translated proteins cause neurotoxicity by inducing ER stress. *Acta Neuropathol* 128: 505–524. [CrossRef](#) [Medline](#)
- Zu T, Liu Y, Bañez-Coronel M, Reid T, Pletnikova O, Lewis J, Miller TM, Harms MB, Falchook AE, Subramony SH, Ostrow LW, Rothstein JD, Troncoso JC, Ranum LP (2013) RAN proteins and RNA foci from antisense transcripts in C9ORF72 ALS and frontotemporal dementia. *Proc Natl Acad Sci USA* 110:E4968–E4977. [CrossRef](#)